NEXLIZET
Peakbempedoic acid and ezetimibe
NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NEXLIZET (bempedoic acid and ezetimibe) is adenosine triphosphate-citrate lyase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXLIZET is a fixed-dose combination oral tablet containing bempedoic acid and ezetimibe, approved in 2020 to reduce LDL cholesterol in patients with hypercholesterolemia. It works by dual mechanism: bempedoic acid inhibits ATP-citrate lyase (an earlier step in cholesterol synthesis) while ezetimibe blocks intestinal cholesterol absorption. This combination targets patients who cannot tolerate statins or require additional LDL reduction.
$47MPart D
Peak14.0 years to LOEProduct is at peak maturity with stable $47M annual Part D spending; commercial teams are focused on market penetration rather than growth, indicating established sales infrastructure and potential for optimization roles.
Mechanism of Action
Adenosine Triphosphate-Citrate Lyase Inhibitors
Pharmacologic Class:
Adenosine Triphosphate-Citrate Lyase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEXLIZET positions you in the mature cardiovascular/lipid management franchise with stable market dynamics and established patient populations. Career growth will center on optimizing market penetration, payer negotiations, and lifecycle extension rather than launch excitement.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.